(HURN) Huron Consulting - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US4474621020
Stock: Consulting, Technology, Software, Advisory
Total Rating 50
Risk 85
Buy Signal 0.13
| Risk 5d forecast | |
|---|---|
| Volatility | 34.1% |
| Relative Tail Risk | -17.2% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.06 |
| Alpha | -11.05 |
| Character TTM | |
|---|---|
| Beta | 0.389 |
| Beta Downside | 0.552 |
| Drawdowns 3y | |
|---|---|
| Max DD | 32.45% |
| CAGR/Max DD | 0.75 |
EPS (Earnings per Share)
Revenue
Description: HURN Huron Consulting March 05, 2026
Huron Consulting Group Inc. (HURN) is a global professional services firm. It operates across Healthcare, Education, and Commercial segments. The company provides financial and operational performance improvement consulting, digital services (including AI and automation), organizational transformation, and revenue cycle managed services. Consulting firms typically offer expertise to optimize client operations and strategy.
HURN also offers research-focused consulting, managed services, and proprietary software, such as the Huron Research product suite. Their services extend to financial and capital advisory, regulatory compliance, and risk management. This business model relies on intellectual capital and client relationships.
The company serves diverse industries, including healthcare, education, financial services, industrials, energy and utilities, and the public sector. Further analysis on ValueRay can provide deeper insights into HURNs market position and financial performance.
Headlines to watch out for
- Healthcare segment revenue growth drives overall performance
- Education segment consulting demand impacts profitability
- Digital services expansion boosts technology-related revenue
- Economic downturns reduce demand for consulting services
- Regulatory changes in healthcare and education create opportunities
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 105.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA -0.57 > 1.0 |
| NWC/Revenue: 3.87% < 20% (prev 4.73%; Δ -0.86% < -1%) |
| CFO/TA 0.13 > 3% & CFO 193.4m > Net Income 105.0m |
| Net Debt (523.8m) to EBITDA (217.2m): 2.41 < 3 |
| Current Ratio: 1.17 > 1.5 & < 3 |
| Outstanding Shares: last quarter (17.9m) vs 12m ago -4.06% < -2% |
| Gross Margin: 31.10% > 18% (prev 0.32%; Δ 3078 % > 0.5%) |
| Asset Turnover: 117.2% > 50% (prev 110.6%; Δ 6.56% > 0%) |
| Interest Coverage Ratio: 5.42 > 6 (EBITDA TTM 217.2m / Interest Expense TTM 34.2m) |
Altman Z'' 3.17
| A: 0.04 (Total Current Assets 448.6m - Total Current Liabilities 383.4m) / Total Assets 1.53b |
| B: 0.42 (Retained Earnings 636.7m / Total Assets 1.53b) |
| C: 0.13 (EBIT TTM 185.4m / Avg Total Assets 1.44b) |
| D: 0.63 (Book Value of Equity 630.7m / Total Liabilities 998.1m) |
| Altman-Z'' Score: 3.17 = A |
Beneish M -2.99
| DSRI: 0.96 (Receivables 390.4m/359.1m, Revenue 1.68b/1.49b) |
| GMI: 1.03 (GM 31.10% / 32.03%) |
| AQI: 1.02 (AQ_t 0.68 / AQ_t-1 0.67) |
| SGI: 1.13 (Revenue 1.68b / 1.49b) |
| TATA: -0.06 (NI 105.0m - CFO 193.4m) / TA 1.53b) |
| Beneish M-Score: -2.99 (Cap -4..+1) = A |
What is the price of HURN shares?
As of March 09, 2026, the stock is trading at USD 144.83 with a total of 226,471 shares traded.
Over the past week, the price has changed by +0.26%, over one month by -5.99%, over three months by -15.32% and over the past year by +0.41%.
Over the past week, the price has changed by +0.26%, over one month by -5.99%, over three months by -15.32% and over the past year by +0.41%.
Is HURN a buy, sell or hold?
Huron Consulting has received a consensus analysts rating of 4.80.
Therefore, it is recommended to buy HURN.
- StrongBuy: 4
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the HURN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 215.5 | 48.8% |
| Analysts Target Price | 215.5 | 48.8% |
HURN Fundamental Data Overview March 09, 2026
P/E Trailing = 24.7997
P/E Forward = 16.9205
P/S = 1.5017
P/B = 4.6364
P/EG = 1.4717
Revenue TTM = 1.68b USD
EBIT TTM = 185.4m USD
EBITDA TTM = 217.2m USD
Long Term Debt = 489.7m USD (from longTermDebt, last quarter)
Short Term Debt = 34.3m USD (from shortTermDebt, last quarter)
Debt = 548.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 523.8m USD (from netDebt column, last quarter)
Enterprise Value = 3.02b USD (2.50b + Debt 548.3m - CCE 24.5m)
Interest Coverage Ratio = 5.42 (Ebit TTM 185.4m / Interest Expense TTM 34.2m)
EV/FCF = 16.51x (Enterprise Value 3.02b / FCF TTM 183.0m)
FCF Yield = 6.06% (FCF TTM 183.0m / Enterprise Value 3.02b)
FCF Margin = 10.88% (FCF TTM 183.0m / Revenue TTM 1.68b)
Net Margin = 6.25% (Net Income TTM 105.0m / Revenue TTM 1.68b)
Gross Margin = 31.10% ((Revenue TTM 1.68b - Cost of Revenue TTM 1.16b) / Revenue TTM)
Gross Margin QoQ = 30.98% (prev 30.55%)
Tobins Q-Ratio = 1.98 (Enterprise Value 3.02b / Total Assets 1.53b)
Interest Expense / Debt = 1.51% (Interest Expense 8.26m / Debt 548.3m)
Taxrate = 29.16% (12.6m / 43.3m)
NOPAT = 131.3m (EBIT 185.4m * (1 - 29.16%))
Current Ratio = 1.17 (Total Current Assets 448.6m / Total Current Liabilities 383.4m)
Debt / Equity = 1.04 (Debt 548.3m / totalStockholderEquity, last quarter 528.6m)
Debt / EBITDA = 2.41 (Net Debt 523.8m / EBITDA 217.2m)
Debt / FCF = 2.86 (Net Debt 523.8m / FCF TTM 183.0m)
Total Stockholder Equity = 499.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 7.32% (Net Income 105.0m / Total Assets 1.53b)
RoE = 21.03% (Net Income TTM 105.0m / Total Stockholder Equity 499.4m)
RoCE = 18.74% (EBIT 185.4m / Capital Employed (Equity 499.4m + L.T.Debt 489.7m))
RoIC = 12.08% (NOPAT 131.3m / Invested Capital 1.09b)
WACC = 6.22% (E(2.50b)/V(3.05b) * Re(7.35%) + D(548.3m)/V(3.05b) * Rd(1.51%) * (1-Tc(0.29)))
Discount Rate = 7.35% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -4.03%
[DCF] Terminal Value 87.30% ; FCFF base≈177.3m ; Y1≈218.7m ; Y5≈372.4m
[DCF] Fair Price = 547.1 (EV 9.78b - Net Debt 523.8m = Equity 9.26b / Shares 16.9m; r=6.22% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 91.27 | EPS CAGR: 48.71% | SUE: 1.48 | # QB: 2
Revenue Correlation: 97.06 | Revenue CAGR: 15.19% | SUE: 3.80 | # QB: 2
EPS next Quarter (2026-06-30): EPS=2.17 | Chg7d=-0.012 | Chg30d=+0.046 | Revisions Net=+2 | Analysts=5
EPS current Year (2026-12-31): EPS=8.77 | Chg7d=+0.006 | Chg30d=+0.024 | Revisions Net=+2 | Growth EPS=+12.0% | Growth Revenue=+9.6%
EPS next Year (2027-12-31): EPS=10.23 | Chg7d=-0.227 | Chg30d=-0.270 | Revisions Net=-1 | Growth EPS=+16.7% | Growth Revenue=+8.7%
[Analyst] Revisions Ratio: +1.00 (2 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.9% (Discount Rate 7.9% - Earnings Yield 4.0%)
[Growth] Growth Spread = +8.2% (Analyst 12.1% - Implied 3.9%)
P/E Forward = 16.9205
P/S = 1.5017
P/B = 4.6364
P/EG = 1.4717
Revenue TTM = 1.68b USD
EBIT TTM = 185.4m USD
EBITDA TTM = 217.2m USD
Long Term Debt = 489.7m USD (from longTermDebt, last quarter)
Short Term Debt = 34.3m USD (from shortTermDebt, last quarter)
Debt = 548.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 523.8m USD (from netDebt column, last quarter)
Enterprise Value = 3.02b USD (2.50b + Debt 548.3m - CCE 24.5m)
Interest Coverage Ratio = 5.42 (Ebit TTM 185.4m / Interest Expense TTM 34.2m)
EV/FCF = 16.51x (Enterprise Value 3.02b / FCF TTM 183.0m)
FCF Yield = 6.06% (FCF TTM 183.0m / Enterprise Value 3.02b)
FCF Margin = 10.88% (FCF TTM 183.0m / Revenue TTM 1.68b)
Net Margin = 6.25% (Net Income TTM 105.0m / Revenue TTM 1.68b)
Gross Margin = 31.10% ((Revenue TTM 1.68b - Cost of Revenue TTM 1.16b) / Revenue TTM)
Gross Margin QoQ = 30.98% (prev 30.55%)
Tobins Q-Ratio = 1.98 (Enterprise Value 3.02b / Total Assets 1.53b)
Interest Expense / Debt = 1.51% (Interest Expense 8.26m / Debt 548.3m)
Taxrate = 29.16% (12.6m / 43.3m)
NOPAT = 131.3m (EBIT 185.4m * (1 - 29.16%))
Current Ratio = 1.17 (Total Current Assets 448.6m / Total Current Liabilities 383.4m)
Debt / Equity = 1.04 (Debt 548.3m / totalStockholderEquity, last quarter 528.6m)
Debt / EBITDA = 2.41 (Net Debt 523.8m / EBITDA 217.2m)
Debt / FCF = 2.86 (Net Debt 523.8m / FCF TTM 183.0m)
Total Stockholder Equity = 499.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 7.32% (Net Income 105.0m / Total Assets 1.53b)
RoE = 21.03% (Net Income TTM 105.0m / Total Stockholder Equity 499.4m)
RoCE = 18.74% (EBIT 185.4m / Capital Employed (Equity 499.4m + L.T.Debt 489.7m))
RoIC = 12.08% (NOPAT 131.3m / Invested Capital 1.09b)
WACC = 6.22% (E(2.50b)/V(3.05b) * Re(7.35%) + D(548.3m)/V(3.05b) * Rd(1.51%) * (1-Tc(0.29)))
Discount Rate = 7.35% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -4.03%
[DCF] Terminal Value 87.30% ; FCFF base≈177.3m ; Y1≈218.7m ; Y5≈372.4m
[DCF] Fair Price = 547.1 (EV 9.78b - Net Debt 523.8m = Equity 9.26b / Shares 16.9m; r=6.22% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 91.27 | EPS CAGR: 48.71% | SUE: 1.48 | # QB: 2
Revenue Correlation: 97.06 | Revenue CAGR: 15.19% | SUE: 3.80 | # QB: 2
EPS next Quarter (2026-06-30): EPS=2.17 | Chg7d=-0.012 | Chg30d=+0.046 | Revisions Net=+2 | Analysts=5
EPS current Year (2026-12-31): EPS=8.77 | Chg7d=+0.006 | Chg30d=+0.024 | Revisions Net=+2 | Growth EPS=+12.0% | Growth Revenue=+9.6%
EPS next Year (2027-12-31): EPS=10.23 | Chg7d=-0.227 | Chg30d=-0.270 | Revisions Net=-1 | Growth EPS=+16.7% | Growth Revenue=+8.7%
[Analyst] Revisions Ratio: +1.00 (2 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.9% (Discount Rate 7.9% - Earnings Yield 4.0%)
[Growth] Growth Spread = +8.2% (Analyst 12.1% - Implied 3.9%)